Metrics to compare | PER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPERPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −4.5x | −0.4x | |
PEG Ratio | −0.02 | 0.01 | 0.00 | |
Price/Book | 1.0x | 3.5x | 2.6x | |
Price / LTM Sales | 9.0x | 17.9x | 3.1x | |
Upside (Analyst Target) | - | 101.5% | 46.0% | |
Fair Value Upside | Unlock | −2.2% | 5.3% | Unlock |
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.